# Clinical Trials Data KRAS - Document 4

# Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas

## Clinical Trial: https://clinicaltrials.gov/study/NCT01380795

"eligibilityCriteria": "Inclusion Criteria:\n\n1. men and women\n2. age over 18 y.o.\n3. signed informed consent form.\n4. Patients barriers of Non-small Cell Lung Cancer Metastatic\n5. chemotherapy non yet begun\n6. patients barrier of CTC\n7. Research for mutation of EGFR and Kras made on the primitive tumor\n8. Man and woman old enough to procreate under effective contraceptives\n\nExclusion Criteria:\n\n1. small cells bronchial cancer\n2. Non metastatic bronchial cancer\n3. Absence of detectable CTC at the patient\n4. Private individuals of freedom or under tutelage (including legal guardianship)\n5. Incapacity to sign the inform consent form or psychiatric, behavioural disorders or geographical situation precluding the follow-up of the protocol\n6. Pregnancy, lactating or refusal of the contraception for women",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KRAS gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided clinical trial eligibility criteria, there is no explicit exclusion of patients with a KRAS mutation. The eligibility criteria include conducting research for mutations of EGFR and KRAS on the primitive tumor, suggesting that having these mutations detetected does not disqualify a patient from participating.  
  
Therefore, a patient with a KRAS gene mutation could potentially be eligible for this clinical trial, as long as they meet the other inclusion criteria and do not fall under any of the exclusion criteria. Specifically, if the patient has non-small cell lung cancer that is metastatic and they have not begun chemotherapy, they might be eligible pending other individual assessments. It would be important, though, to get a final confirmation from the clinical trial coordinators for any specific nuances that might not be stated in the general criteria.